{"id":"NCT00337610","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus","officialTitle":"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2007-05","completion":"2007-08","firstPosted":"2006-06-16","resultsPosted":"2010-05-27","lastUpdate":"2016-05-12"},"enrollment":190,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus (T2DM)"],"interventions":[{"type":"DRUG","name":"sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day","otherNames":["Januvia"]},{"type":"DRUG","name":"comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day","otherNames":[]}],"arms":[{"label":"sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day","type":"EXPERIMENTAL"},{"label":"sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day","type":"PLACEBO_COMPARATOR"}],"summary":"A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.","primaryOutcome":{"measure":"Change From Baseline in A1C at Week 18","timeFrame":"Baseline and Week 18","effectByArm":[{"arm":"Sitagliptin 100 mg","deltaMin":-1,"sd":null},{"arm":"Placebo","deltaMin":0.02,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18194595"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":96},"commonTop":["Blood Glucose Increased","Nasopharyngitis","Diarrhoea","Pharyngitis"]}}